Protein Aggregation and Fibrillogenesis in Cerebral and Systemic Amyloid Disease

1. Introduction and Technical Survey. - 2. Fibril Formation by Short Synthetic Peptides. - 3. In vitro Oligomerization and Fibrillogenesis of Amyloid-beta Peptides. - 4. Tau Fibrillogenesis. - 5. Prion protein Aggregation and Fibrillogenesis In vitro. - 6. α-Synuclein Aggregation and Modulating Factors. - 7. Pathological Self-aggregation of β₂-microglobulin: A Challenge for Protein Biophysics. - 8. Islet amyloid polypeptide – Aggregation and fibrillogenesis in vitro and its Inhibition. - 9. Mechanisms of Transthyretin Aggregation and Toxicity. - 10. Fibrillogenesis of Huntingtin and Other Glutamine Containing Proteins. - 11. Aggregation and Fibrillogenesis of Proteins not Associated with Disease – A few Case Studies. - 12. Experimental Inhibition of Peptide Fibrillogenesis by Synthetic Peptides, Carbohydrates and Drugs. - 13. Experimental inhibition of fibrillogenesis and neurotoxicity by amyloid-beta (Aβ) and other disease-related peptides/proteins by plant extracts and herbal compounds. - 14. Alzheimer’s  Disease. - 15. Modeling the Polyglutamine Aggregation Pathway in Huntington’s Disease: from Basic Studies to Clinical Applications. - 16. Parkinson’s Disease. - 17. Human Prion Diseases: From Kuru to Variant Creutzfeldt-Jakob Diseasae. - 18. Animal Prion Diseases. - 19. β₂-microglobulin Amyloidosis. - 20. Systemic AA Amyloidosis. - 21. Familial Amyloidotic Polyneuropathy and Transthyretin. - 22. The Challenge of Systemic Immunoglobulin Light-chain Amyloidosis (AL).